A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether mammalian target of rapamycin inhibitor everolimus can improve intellectual disability, autism, and other neuropsychological deficits in children with tuberous sclerosis complex (TSC). METHODS: In this 12-month, randomized, double-blind, placebo-controlled trial, we attempted to enroll 60 children with TSC and IQ <80, learning disability, special schooling, or autism, aged 4-17 years, without intractable seizures to be assigned to receive everolimus or placebo. Everolimus was titrated to blood trough levels of 5-10 ng/mL. Primary outcome was full-scale IQ; secondary outcomes included autism, neuropsychological functioning, and behavioral problems. RESULTS: Thirty-two children with TSC were randomized. Intention-to-treat analysis showed no benefit of everolimus on full-scale IQ (treatment effect -5.6 IQ points, 95% confidence interval -12.3 to 1.0). No effect was found on secondary outcomes, including autism and neuropsychological functioning, and questionnaires examining behavioral problems, social functioning, communication skills, executive functioning, sleep, quality of life, and sensory processing. All patients had adverse events. Two patients on everolimus and 2 patients on placebo discontinued treatment due to adverse events. CONCLUSIONS: Everolimus did not improve cognitive functioning, autism, or neuropsychological deficits in children with TSC. The use of everolimus in children with TSC with the aim of improving cognitive function and behavior should not be encouraged in this age group. CLINICALTRIALSGOV IDENTIFIER: NCT01730209. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for children with TSC, everolimus does not improve intellectual disability, autism, behavioral problems, or other neuropsychological deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice
Tsai, P. T., Hull, C., Chu, Y., Greene-Colozzi, E., Sadowski, A. R., Leech, J. M., Steinberg, J., Crawley, J. N., Regehr, W. G., & Sahin, M. (2012) · Nature · doi:10.1038/nature11310 · Cited by 888
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model
Silva-Santos, S., van Woerden, G. M., Bruinsma, C. F., Mientjes, E., Jolfaei, M. A., Distel, B., Kushner, S. A., & Elgersma, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80554 · Cited by 238
Self-citationEverolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
Krueger, D. A., Sadhwani, A., Byars, A. W., de Vries, P. J., Franz, D. N., Whittemore, V. H., Filip‐Dhima, R., Murray, D., Kapur, K., & Sahin, M. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.494 · Cited by 133 · cited 2×
“These results are in line with a recently published trial that found no benefit of 6 months everolimus treatment in 47 patients with TSC aged 6–21 years on behavior.(13) Since at the time of trial design no previous clinical trials in patients with TSC had been reported with preregistered cognitive assessments as prim…”
BackgroundResult
Cited by
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L.-S., Long, S., Ke, X.-Y., Fukunaga, K., Lu, Y.-M., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 258
Epilepsy in the mTORopathies: opportunities for precision medicine
Moloney, P. B., Cavalleri, G. L., & Delanty, N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab222 · Cited by 125
Specchio, N., Nabbout, R., Aronica, E., Auvin, S., Benvenuto, A., de Palma, L., Feucht, M., Jansen, F., Kotulska, K., Sarnat, H., et al. (2023) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2023.08.005 · Cited by 58
Self-citationBennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex
Karalis, V., Caval-Holme, F., & Bateup, H. S. (2022) · Nature Communications · doi:10.1038/s41467-022-31961-6 · Cited by 40
Metadata
- Authors
- Overwater, I. E., Rietman, A. B., Mous, S. E., Bindels-de Heus, K., Rizopoulos, D., ten Hoopen, L. W., van der Vaart, T., Jansen, F. E., Elgersma, Y., Moll, H. A., & de Wit, M.-C. Y.
- Venue
- Neurology
- Published
- 2019-07-09
- Volume
- 93
- Issue
- 2
- Pages
- e200-e209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2953115047
- Cited by
- 120
- References
- 6
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. https://app.cochat.ai/papers/10.1212/wnl.0000000000007749
- The paper
- Overwater, I. E., Rietman, A. B., Mous, S. E., Bindels-de Heus, K., Rizopoulos, D., ten Hoopen, L. W., van der Vaart, T., Jansen, F. E., Elgersma, Y., Moll, H. A., & de Wit, M.-C. Y. (2019). A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology. https://doi.org/10.1212/wnl.0000000000007749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.